These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 23828807)

  • 21. [Incretin-based therapy for treating patients with type 2 diabetes].
    Jermendy G
    Orv Hetil; 2011 Nov; 152(48):1931-40. PubMed ID: 22071295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospects for incretin-related drugs].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():703-6. PubMed ID: 22768602
    [No Abstract]   [Full Text] [Related]  

  • 23. Incretins and their role in the management of diabetes.
    Frias JP; Edelman SV
    Curr Opin Endocrinol Diabetes Obes; 2007 Aug; 14(4):269-76. PubMed ID: 17940451
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GLP-1 receptor agonists: targeting both hyperglycaemia and disease processes in diabetes.
    Holst JJ; Seino Y
    Diabetes Res Clin Pract; 2009 Jul; 85(1):1-3. PubMed ID: 19299027
    [No Abstract]   [Full Text] [Related]  

  • 25. The future of incretin-based therapy: novel avenues--novel targets.
    Ahrén B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():158-66. PubMed ID: 21824270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current and emerging therapies: an overview of incretin-based therapy in the management of type 2 diabetes.
    Pratley RE
    J Am Acad Nurse Pract; 2008 Nov; 20 Suppl 1():7-11. PubMed ID: 19402254
    [No Abstract]   [Full Text] [Related]  

  • 27. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 28. Targeting the incretin system in type 2 diabetes mellitus.
    Potenza M; Rayfield EJ
    Mt Sinai J Med; 2009 Jun; 76(3):244-56. PubMed ID: 19421968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incretin therapy and its effect on body weight in patients with diabetes.
    Lind M
    Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
    Madsbad S; Krarup T; Deacon CF; Holst JJ
    Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
    Peterson G
    Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [DPP-IV inhibitors and GLP-1 analogues].
    Zettl H; Steinhilber D
    Pharm Unserer Zeit; 2010 Mar; 39(2):108-13. PubMed ID: 20196037
    [No Abstract]   [Full Text] [Related]  

  • 33. Combination pharmacotherapy with incretins: what works best and when?
    Over RK; Ratner RE
    Curr Diab Rep; 2008 Oct; 8(5):361-7. PubMed ID: 18778584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 36. Incretin-based therapies: review of current clinical trial data.
    Peters A
    Am J Med; 2010 Mar; 123(3 Suppl):S28-37. PubMed ID: 20206729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Beta-cell function in the foreground. GLP-1 based therapy of type 2 diabetes].
    Kern W
    MMW Fortschr Med; 2010 Jan; 151 Suppl 4():173-8. PubMed ID: 21595145
    [No Abstract]   [Full Text] [Related]  

  • 38. Incretin effects on β-cell function, replication, and mass: the human perspective.
    Garber AJ
    Diabetes Care; 2011 May; 34 Suppl 2(Suppl 2):S258-63. PubMed ID: 21525465
    [No Abstract]   [Full Text] [Related]  

  • 39. Type 2 diabetes: epidemiology and treatment, pathophysiology, new therapeutics, and the evolving role of the pharmacist.
    Campbell RK; Neumiller JJ; White J; Sisson E; Kuhn C
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S2. PubMed ID: 19801362
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.